DEA Vs. White House: Agency Pushes Back On Medical Benefits Of Cannabis, Weed Stocks Wobble
In addition to reportedly doubting the scientific evidence presented by HHS, the DEA also expressed concern about the increasing potency of THC, the psychoactive compound in cannabis. Marijuana advocates and stakeholders question the motivations behind these anonymous claims, as the DEA itself has not publicly opposed the recommendation. The agency is conducting its own review, with Administrator Anne Milgram promising to consider all available research.
